Omnitura’s Leadership Team is comprised of pioneers who have led a diversity of industries in innovation and change. Our shared belief in the need to develop omnivalent therapies that address the complex and heterogeneous nature of cancer serves as the foundation that inspires us and our collaborators to develop new medical solutions that address patient needs as well as issues of affordability and accessibility. Most of Omnitura’s board members have served for over a decade, demonstrating their long-term commitment to the vision and social impact of Omnitura.
James Dao | Chairman and Co-Founder
James Dao, educated in engineering physics at UC Berkeley, is a successful serial, high tech inventor and entrepreneur based in Silicon Valley and Las Vegas with over 45 years of experience in managing, inventing, developing and commercializing advanced technologies and innovative applications. Mr. Dao is known for creating successful commercialization of innovative products and business concepts by (1) focusing on objectives to benefit end users and society, (2) implementing out-of-the-box-thinking to reduce technical and financial risks, (3) creating win-win collaborations with like-minded individuals, academic institutions, government research centers and industry, (4) defining measurable outcomes for all collaborators in terms of Goodness, Glory and Gold. Based on these business principles Mr. Dao's innovative companies have stimulated successful paradigm shifts in their industries.
Mr. Dao co-founded Genyous, Inc. in 2000 to implement a vision of addressing cancer and comorbidities with a strategy based on systems biology considerations. This strategy led to the creation of a diagnostic and pharmaceutical drug development platform for non-toxic, multivalent molecularly directed therapies. Omnitura Therapeutics, Inc. is the second company to spin out from Genyous, Inc. to focus on commercializing Aneustat™, the world’s first multivalent immune-oncology drug candidate to treat cancer and co-existing chronic diseases.
Under Mr. Dao's leadership, Omnitura’s clinical trial team members and collaborators are among the best in the clinical research profession and industry. Mr. Dao believes that Omnitura is ready to demonstrate a new paradigm in oncology to cure prostate cancer via a series of three clinical trials and within the next two years begin licensing to various pharmaceutical companies for distribution to patients in 2021.
David Alberts, M.D., | Director
Dr. Alberts serves as Omnitura's Clinical Science Advisor for cancer prevention. Dr. Alberts recently retired as director of the Arizona Cancer Center at the University of Arizona. He is a recognized leader in research in the prevention of cancer. He is a Regents Professor of Medicine, Pharmacology, Nutritional Sciences, Public Health, and BIO5 Institute, the University of Arizona, Tucson, Arizona.
Dr. Alberts has been funded by the National Cancer Institute yearly since 1971 for laboratory and clinical research related to the clinical pharmacology of cancer chemotherapy and chemo preventive agents, as well as the development of research strategies for the prevention of breast, cervix, colon, prostate and skin cancers. Dr. Alberts has authored or co-authored more than 400 peer-reviewed publications, has served as editor and co-editor of four books and has served on several editorial boards.
Thomas Kalinske | Director
Thomas Kalinske has extensive experience serving as the top executive of numerous dynamic multi-billion-dollar international businesses. Mr. Kalinske currently serves as Vice Chairman of the Board of Leapfrog Enterprises Inc. He has served as Leapfrog’s CEO and on its Board of Directors since 1997 and as Chairman of its Board of Directors from 1997 to 2004. Mr. Kalinske is also Chairman of Cambium Learning Group (NASDQ: ABCD), an education company that provides curriculum for K-12 students with special needs and learning difficulties, as well as turnaround services for public schools. Additionally, Mr. Kalinske is Executive Chairman of Global Education Learning, a company currently engaged in buying and building education companies in China that provide services and a learning path for young children two - seven years old.
Mr. Kalinske also served for 20 years on the Board of the Milken Family Foundation, which is dedicated to improving health, finding cures for prostate and breast cancers, and improving education. He also served on the RAND Advisory Board for Education and Health issues and the National Education Association Foundation Board for 10 years. He has been recognized as Man of the Year by the Starlight Foundation, the Boy Scouts of America, and is one of 15 living Americans inducted in the US "Toy Industry Hall of Fame".
Jerry Norskog | Co-Founder, Director and Audit Committee Member
Mr. Norskog serves as Omnitura's Executive Vice President of Strategy & Business Development. As a member of the board of directors, Mr. Norskog provides valuable insight on the global pharmaceutical markets and guidance on the cultivation of joint ventures and manufacturing & distribution alliances. Mr. Norskog has over thirty years of experience in the pharmaceutical industry. He held numerous senior management positions for various divisions of Johnson & Johnson in North America and throughout Asia Pacific. His Asia experience includes serving as President of Xian-Janssen Pharmaceutical Ltd., a Johnson & Johnson joint venture with the Chinese Government, which was ranked among the top ten best ventures in China since 1991. Mr. Norskog also served as President of Johnson & Johnson China Development.
John Ruckdeschel, M.D. | Director
Dr. Ruckdeschel, chairs Omnitura’s translational research programs to maximize trial success and to accelerate the medical paradigm shift using multivalent therapies to simultaneously treat heterogeneous cancers and coexisting chronic diseases.
Dr. Ruckdeschel is the Director of the Cancer Institute of the University of Mississippi Medical Center and Ergon Chair in Cancer Research. He has a rich and broad background in developing focused cancer research and a national reputation as an established leader in cancer research and management.
Dr. Ruckdeschel who previously served as the Director of the Moffitt Cancer Center in Tampa, Florida, led that institution to National Cancer Institute (NCI) Comprehensive Cancer Center designation and to become the third-largest clinical cancer program in the United States. He then moved to the Barbara Ann Karmanos Cancer Center in Detroit where he re-acquired its NCI comprehensive status and completed the process of making Karmanos a free-standing cancer hospital. In both settings, he built strong clinical networks by working with community physicians and patients, developing effective interdisciplinary clinical teams and creating strong programs across clinical, basic, translational and population research.
Best known for his work in lung cancer, he was the Chairman of the Eastern Cooperative Oncology Group’s (ECOG) lung (now thoracic) core committee. He served the National Cancer Institute as Toxicity Committee chair for ECOG that wrote the original Common Toxicity Criteria. Dr. Ruckdeschel is a prolific author. He has written and co-written more than 350 publications, book chapters and abstracts and has given more than 500 invited presentations.
Simon Sutcliffe, M.D. | Director and Vice Chairman focusing on Societal Impact
Dr. Sutcliffe is currently the Chief Medical Officer of Omnitura. In this capacity, he oversees the medical science, clinical development strategies, and the exploration of unmet medical needs that are well served by the Company's systems approach to therapy.
Dr. Sutcliffe has a broad medical career including research in microbiology and immunology, clinical research in oncology, and leadership in the management of cancer care institutions and organizations. He was a Professor of Radiology at the University of Toronto, and was the President and CEO of the Ontario Cancer Institute/Princess Margaret Hospital in Toronto, Canada. Dr. Sutcliffe has published extensively in the area of radiation and medical oncology as applied to the treatment of lymphoma, leukemia and endocrine malignancies, fertility and gonadal functions in cancer patients, and cellular immuno-deficiency and immuno-modulation in cancer. From 2000 to 2008 Dr. Sutcliffe served as President of the British Columbia Cancer Agency (BCCA) in Vancouver, B.C., Canada.
In January 2009 Dr. Sutcliffe was appointed Chairman of the Canadian Cancer Control Organization. Dr. Sutcliffe also serves as the President of the International Cancer Control Congress and President of Two Worlds Cancer Collaboration (the Canadian branch of the International Network for Cancer Treatment and Research). Through these programs, Dr. Sutcliffe is actively involved in cancer-related healthcare projects in India, Nepal, Brazil and Tanzania.
Lee Ting | Director and Audit Committee Member
Mr. Ting currently serves as a Managing Partner of WR Hambrecht Ventures I and II, an affiliate of WR Hambrecht+Co, an investment bank based in San Francisco. He is an independent Board Member of the Lenovo Group, a leading global IT company based in the US and China, and Neophotonics Inc., a global supplier of optical components and modules to the telecommunications industry based in San Jose, CA. Mr. Ting is a former Corporate Vice President of Hewlett Packard Co. (HP) where he served for more than thirty years. His last position at HP was Corporate Vice President and Managing Director of Worldwide Geographic Operations. During a two-year absence from HP in the late eighties, Mr. Ting was a Senior Vice President of Hambrecht & Quist where he played a key role in the expansion of the firm's venture capital business into Asia.
Jack Troia | Director and Audit Committee Chair
Jack Troia was a partner at Deloitte & Touche for fourteen years and in public accounting for over twenty-five years. Mr. Troia was a National Director of the Financial Services Practice and responsible for the financial services groups in the local offices of Deloitte & Touche in Washington, DC and Milwaukee, Wisconsin. He has significant experience in accounting and auditing for public and private companies, mergers and acquisitions, initial and secondary public offerings, financial management, and general business matters. Over the years he has worked with a significant number of businesses, in all aspects of financial management, business planning, accounting, and information systems.
After retiring from Deloitte & Touche, Mr. Troia assumed a position at Georgetown University as an adjunct professor. For over five years Mr. Troia was involved with dynamic growing companies as both COO and CFO. He was responsible for all financial and operating aspects including accounting, treasury, human resources, management information systems, and operations.
David Wilson, Ph.D. | Director
Dr. David Wilson, as Chief Operating Officer, is responsible for the Omnitura clinical development program and strategic objectives. In addition, Dr. Wilson serves as the primary liaison to the FDA and has developed relationships to engage the agency and advance Aneustat™ as the foundational drug for the treatment of cancer. Dr. Wilson has an excellent track record of bringing new pharmaceutical products through different phases of research, development and commercialization, including currently marketed products such as the immuno-oncology drugs Yervoy™ and Opdivo™. His strengths are strategic planning and resourceful, hands-on tactical management in focused product development projects from laboratory to launch, creation of operational infrastructure to support technology development, and leading multifunctional teams to optimize the values of science.